Outset Medical, Inc. (OM)
Largest Insider Buys in Sector
OM Stock Price History Chart
OM Stock Performance
About Outset Medical, Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Insider Activity of Outset Medical, Inc.
Over the last 12 months, insiders at Outset Medical, Inc. have bought $0 and sold $1.03M worth of Outset Medical, Inc. stock.
On average, over the past 5 years, insiders at Outset Medical, Inc. have bought $701,878 and sold $425.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,500 shares for transaction amount of $133,800 was made by Hinrichs James F. (director) on 2022‑11‑22.
List of Insider Buy and Sell Transactions, Outset Medical, Inc.
| 2024-08-15 | Sale | Chair and CEO | 5,308 0.0098% | $0.84 | $4,459 | 0.00% | ||
| 2024-08-15 | Sale | Chief Financial Officer | 3,971 0.0073% | $0.84 | $3,336 | 0.00% | ||
| 2024-08-15 | Sale | SVP Operations and R&D | 1,293 0.0024% | $0.84 | $1,086 | 0.00% | ||
| 2024-08-15 | Sale | General Counsel | 3,011 0.0056% | $0.84 | $2,529 | 0.00% | ||
| 2024-07-24 | Sale | SVP Operations and R&D | 723 0.0015% | $4.02 | $2,906 | -7.71% | ||
| 2024-06-12 | Sale | General Counsel | 10,569 0.0229% | $4.78 | $50,520 | -86.53% | ||
| 2024-06-03 | Sale | director | 38,117 0.073% | $3.78 | $144,234 | -83.16% | ||
| 2024-05-16 | Sale | Chair and CEO | 5,237 0.0102% | $3.53 | $18,487 | -79.87% | ||
| 2024-05-16 | Sale | Chief Financial Officer | 3,918 0.0076% | $3.53 | $13,831 | -79.87% | ||
| 2024-05-16 | Sale | General Counsel | 2,972 0.0058% | $3.53 | $10,491 | -79.87% | ||
| 2024-05-16 | Sale | SVP Operations and R&D | 1,097 0.0021% | $3.53 | $3,872 | -79.87% | ||
| 2024-05-10 | Sale | Chief Technology Officer | 8,306 0.0175% | $3.27 | $27,161 | -71.43% | ||
| 2024-03-15 | Sale | SVP Operations and R&D | 2,391 0.0046% | $2.13 | $5,093 | +3.00% | ||
| 2024-03-01 | Sale | Chief Financial Officer | 1,584 0.0032% | $3.15 | $4,990 | -25.81% | ||
| 2024-02-15 | Sale | Chair and CEO | 5,320 0.011% | $3.57 | $18,992 | -31.97% | ||
| 2024-02-15 | Sale | Chief Commercial Officer | 2,500 0.0052% | $3.57 | $8,925 | -31.97% | ||
| 2024-02-15 | Sale | Chief Financial Officer | 4,403 0.0091% | $3.57 | $15,719 | -31.97% | ||
| 2024-02-15 | Sale | Chief Technology Officer | 1,866 0.0039% | $3.57 | $6,662 | -31.97% | ||
| 2024-02-15 | Sale | General Counsel | 3,341 0.0069% | $3.57 | $11,927 | -31.97% | ||
| 2024-02-15 | Sale | SVP Operations and R&D | 617 0.0013% | $3.57 | $2,203 | -31.97% |
Insider Historical Profitability
| Ahmed Nabeel | Chief Financial Officer | 314988 0.6047% | $0.63 | 1 | 26 | +13.17% |
| Brottem John L. | General Counsel | 230295 0.4421% | $0.63 | 1 | 42 | <0.0001% |
| Vazquez Martin | Chief Operating Officer | 103112 0.198% | $0.63 | 1 | 28 | <0.0001% |
| Hinrichs James F. | director | 47668 0.0915% | $0.63 | 3 | 0 | +3.25% |
Institutional Investor Ownership
| Fidelity Investments | $15.42M | 13.43 | 6.95M | -1.68% | -$263,982.43 | <0.01 | |
| Ameriprise Financial | $11.35M | 9.88 | 5.11M | +71.41% | +$4.73M | <0.01 | |
| Morgan Stanley | $8.91M | 7.76 | 4.01M | +3.72% | +$319,262.65 | <0.01 | |
| BlackRock | $7.25M | 6.32 | 3.27M | -13.94% | -$1.17M | <0.0001 | |
| JPMorgan Chase | $6.91M | 6.02 | 3.11M | -37.22% | -$4.1M | <0.01 |